Mirador Therapeutics
3 known investors
Mirador discovers and develops precision medicines for immune-mediated and immuno-fibrotic diseases using a target-patient matching approach. The company targets therapeutics to improve treatment efficacy beyond current standards in immunology and fibrotic conditions.
AI & Machine LearningMedical Devices
Investors · 3
In the news
- State Affairs Secures $70M Funding From Founders Fund Khosla Ventures And Others<!-- --> | TradedVCtraded.co · 2026
- Jasper Closes Kira Deal, Extends Cash Runway - Jasper Therapeutics (NASDAQ:JSPR) - Benzingabenzinga.com · 2026
- Mirador Therapeutics Expands Precision Immunology Portfolio with Exclusive License to KP-301, a Long-Acting Anti-C5a Antibody - BioSpacebiospace.com · 2026
- Jasper Therapeutics Completes Kira Pharmaceuticals Acquisition and Announces $132 Million Private Placement and KP-301/KP-402 Out-Licensing to Mirador Therapeutics | Quiver Quantitativequiverquant.com · 2026
- Mirador Raises $250M in Series B Fundingfinsmes.com · 2026
- Mirador Therapeutics raises over $400 mln in early funding rounds | Reutersreuters.com · 2024